Amy E. Newton

发表

Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus

Laszlo Kiss, R. Pieschl, J. Graef, 2015, Brain Research.

Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.

R. Pieschl, L. Bristow, A. Fernandes, 2015, European journal of pharmacology.

Discovery of a cyclopentylamine as an orally active dual NK1 receptor antagonist-serotonin reuptake transporter inhibitor.

J. Macor, R. Westphal, R. Bertekap, 2014, Bioorganic & medicinal chemistry letters.

Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.

J. Macor, R. Westphal, R. Bertekap, 2013, Bioorganic & medicinal chemistry.

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2018, Journal of medicinal chemistry.

Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.

S. Dworetzky, Ronald J. Knox, C. Polson, 2003, Journal of medicinal chemistry.

Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.

Andrea Mcclure, Ping Chen, N. Meanwell, 2017, Bioorganic & medicinal chemistry.

NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test

J. Macor, R. Pieschl, T. Molski, 2013, Neuropharmacology.

Behavioral and Pharmacological Validation of the Gerbil Forced-Swim Test: Effects of Neurokinin-1 Receptor Antagonists

N. Lodge, Amy E. Newton, J. McElroy, 2008, Neuropsychopharmacology.

(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.

V. Gribkoff, S. Dworetzky, Ronald J. Knox, 2003, Journal of medicinal chemistry.

Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.

J. Macor, R. Pieschl, M. Parker, 2013, Bioorganic & medicinal chemistry letters.

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2017, Journal of medicinal chemistry.

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2017, Journal of medicinal chemistry.

Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.

J. Macor, R. Pieschl, M. Parker, 2013, Bioorganic & medicinal chemistry letters.

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder

J. Macor, A. Mathur, B. Srikumar, 2017, The Journal of Pharmacology and Experimental Therapeutics.